A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
Development pipeline targeting large medical needs
AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products
Key News
SEPTEMBER 29, 2023
Orexo is celebrating 10 years on the US Pharma market
SEPTEMBER 26, 2023
Our skilled RnD team in Uppsala, Sweden, is looking for a master student to write a thesis paper on drug delivery.
SEPTEMBER 18, 2023
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
To read all NEWS go to Media in the top menu
Key financial figures
Group net revenue
634 MSEK
Last Twelve Months, Q322-Q223
Group EBITDA
-121 MSEK
Last Twelve Months, Q322-Q223
US Pharma segment EBIT
293 MSEK
Last Twelve Months, Q322-Q223
Cash position
251 MSEK
Q223